Payment overview · 2025
General Payments
$743.99
43 reported records · 16 companies
Healthcare provider profile · identity verified
Viral Patel, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CRITTENDEN, KY · NPI 1003012428
Verified facts
What the public records show
CMS Open Payments records show Viral Patel, D.O. received $743.99 in general payments during 2025 across 43 reported records.
ABBVIE INC. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.13 | 26.6% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.45 | 8.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.67 | 7.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $51.28 | 6.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.19 | 6.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.14 | 6.2% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $35.26 | 4.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.86 | 4.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.52 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.26 | 4.6% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.38 | 4.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.06 | 4.0% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $29.55 | 4.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.86 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.28 | 2.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.10 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $743.99 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.86 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.59 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.95 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $51.28 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.19 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.14 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.14 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.86 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.83 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 136 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 808 | 246 |
| Levothyroxine Sodium | Levothyroxine Sodium | 569 | 157 |
| Prednisone | Prednisone | 416 | 275 |
| Gabapentin | Gabapentin | 405 | 66 |
| Omeprazole | Omeprazole | 404 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 112 |
| Lisinopril | Lisinopril | 398 | 122 |
| Losartan Potassium | Losartan Potassium | 375 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 108 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 78 |
| Metformin Hcl | Metformin Hcl | 225 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 198 | 57 |
| Trazodone Hcl | Trazodone Hcl | 198 | 50 |
| Lorazepam | Lorazepam | 176 | 33 |
| Alprazolam | Alprazolam | 175 | 19 |
| Furosemide | Furosemide | 167 | 68 |
| Meloxicam | Meloxicam | 160 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 150 | 33 |
| Tramadol Hcl | Tramadol Hcl | 146 | 32 |
| Allopurinol | Allopurinol | 142 | 42 |
| Eliquis | Apixaban | 136 | 26 |
| Glimepiride | Glimepiride | 133 | 39 |
| Sertraline Hcl | Sertraline Hcl | 133 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 129 | 29 |
| Cephalexin | Cephalexin | 126 | 99 |
| Clonazepam | Clonazepam | 126 | 15 |
| Diazepam | Diazepam | 119 | 20 |
| Methylprednisolone | Methylprednisolone | 119 | 105 |
| Azithromycin | Azithromycin | 117 | 100 |
| Montelukast Sodium | Montelukast Sodium | 114 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 28 |
| Potassium Chloride | Potassium Chloride | 111 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 31 |
| Levofloxacin | Levofloxacin | 109 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 32 |
| Carvedilol | Carvedilol | 102 | 36 |
| Alendronate Sodium | Alendronate Sodium | 101 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 31 |
| Simvastatin | Simvastatin | 99 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 29 |
| Buspirone Hcl | Buspirone Hcl | 94 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 94 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 27 |
| Spironolactone | Spironolactone | 84 | 28 |
| Metformin Hcl Er | Metformin Hcl | 82 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 34 |
| Methocarbamol | Methocarbamol | 74 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 23 |
| Fluconazole | Fluconazole | 71 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 14 |
| Memantine Hcl | Memantine Hcl | 67 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 35 |
| Xarelto | Rivaroxaban | 61 | 13 |
| Mupirocin | Mupirocin | 60 | 50 |
| Bupropion Xl | Bupropion Hcl | 58 | 19 |
| Ezetimibe | Ezetimibe | 58 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 58 | 14 |
| Synthroid | Levothyroxine Sodium | 57 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 19 |
| Pregabalin | Pregabalin | 54 | suppressed |
| Baclofen | Baclofen | 53 | 17 |
| Promethazine Hcl | Promethazine Hcl | 53 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Donepezil Hcl | Donepezil Hcl | 51 | 14 |
| Ibuprofen | Ibuprofen | 51 | 11 |
| Warfarin Sodium | Warfarin Sodium | 50 | 14 |
| Amoxicillin | Amoxicillin | 49 | 43 |
| Famotidine | Famotidine | 49 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 40 |
| Jardiance | Empagliflozin | 47 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 15 |
| Farxiga | Dapagliflozin Propanediol | 46 | 17 |
| Sodium Chloride | 0.9 % Sodium Chloride | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 37 |
| Meclizine Hcl | Meclizine Hcl | 45 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 14 |
| Glipizide | Glipizide | 41 | 15 |
| Valacyclovir | Valacyclovir Hcl | 40 | 19 |
| Topiramate | Topiramate | 39 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 32 |
| Ozempic | Semaglutide | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Finasteride | Finasteride | 32 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Temazepam | Temazepam | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Sucralfate | Sucralfate | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Etodolac | Etodolac | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $743.99 · 43 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAMZYOS, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE 3, HETLIOZ, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error